Transferrin, cholesterol and aluminium in Alzheimer's disease

Corrigan, Frank M.; Crichton, J.S.; Rhijn, A. G. Van; Skinner, E. R.; Ward, Neil

doi:10.1016/0009-8981(92)90111-3

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DS patients were observed to absorb aluminum approximately six times more efficiently than agematched controls from a standardized aluminum dose at the physiological level (p < 0.05) and four times more efficiently from an aluminum dose at the pharmacological level (p < 0.001) [41]. AD subjects also absorb aluminum more efficiently than age-matched controls [42] and have higher serum/plasma aluminum levels [43][44][45][46][47][48].…”

Section: Up-regulated Expression Of the App Gene And App Accumulationmentioning

confidence: 99%

APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease

Walton¹,

Wang

2009

Journal of Inorganic Biochemistry

140

View full text Add to dashboard Cite

Section: Up-regulated Expression Of the App Gene And App Accumulationmentioning

confidence: 99%

APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease

Walton¹,

Wang

2009

Journal of Inorganic Biochemistry

140

View full text Add to dashboard Cite

“…In this context, numerous studies have evaluated the association between the risk of AD and content of these toxic metals in circulatory system (serum/plasma, and blood). For example, several studies have observed higher levels of Al in the circulation of AD patients [16][17][18][19][20][21][22][23], whereas B. Bobba reported lower levels of Al in serum (p < 0.05) [24], and other studies demonstrated no significance of Al level between AD and control [25,26]. Moreover, several meta-analyses of Al reported inconsistent results [27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Circulatory Levels of Toxic Metals (Aluminum, Cadmium, Mercury, Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review

Zhang

Liu

et al. 2018

JAD

View full text Add to dashboard Cite

show abstract

“…AD patients absorb about 64% more aluminum than age-matched controls from a standardized dietary aluminum dose [152]. Consequently, AD patients have higher plasma/serum aluminum levels than controls [153][154][155][156][157][158][159].…”

Section: Aluminum Absorption and Plasma Aluminum Levels In Admentioning

confidence: 99%

Aluminum Involvement in the Progression of Alzheimer's Disease

Walton

2013

JAD

111

View full text Add to dashboard Cite

The neuroanatomic specificity with which Alzheimer's disease (AD) progresses could provide clues to AD etiopathology. Magnetic resonance imaging studies of AD clinical progression have confirmed general conclusions from earlier studies of AD neuropathological progression wherein neurofibrillary tangle pathology was observed to spread along a well-defined sequence of corticocortical and corticosubcortical connections, preferentially affecting certain cell types, while sparing others. Identical and non-identical twin studies have consistently shown AD has mixed (environmental and genetic) etiopathogenesis. The decades-long prodromal phase over which AD develops suggests slow but progressive accumulation of a toxic or infective agent over time. Major environmental candidates are reviewed to assess which best fits the profile of an agent that slowly accrues in susceptible cell types of AD-vulnerable brain regions to toxic levels by old age, giving rise to AD neuropathology without rapid neuronal lysis. Chronic aluminum neurotoxicity best matches this profile. Many humans routinely ingest aluminum salts as additives contained in processed foods and alum-treated drinking water. The physical properties of aluminum and ferric iron ions are similar, allowing aluminum to use mechanisms evolved for iron to enter vulnerable neurons involved in AD progression, accumulate in those neurons, and cause neurofibrillary damage. The genetic component of AD etiopathogenesis apparently involves a susceptibility gene, yet to be identified, that increases aluminum absorption because AD and Down syndrome patients have higher than normal plasma, and brain, aluminum levels. This review describes evidence for aluminum involvement in AD neuropathology and the clinical progression of sporadic AD.

show abstract

Transferrin, cholesterol and aluminium in Alzheimer's disease

Cited by 8 publications

References 11 publications

APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease

APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease

Circulatory Levels of Toxic Metals (Aluminum, Cadmium, Mercury, Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review

Aluminum Involvement in the Progression of Alzheimer's Disease

Contact Info

Product

Resources

About